Compare Honeywell International Inc (HON) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs IDEXX Laboratories, Inc. — how do they compare? Honeywell International Inc trades at $232.35 (market cap $72.93B), while IDEXX Laboratories, Inc. trades at $571.23 (market cap $46.22B). The key difference: Honeywell International Inc is the larger of the two by market cap, and Honeywell International Inc pays a 1.22% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| HON | IDXX | |
|---|---|---|
Market Cap | $72.93B | $46.22B |
Sector | Industrials | Health |
52-Week High | $248.79 | $766.68 |
52-Week Low | $188.14 | $526.44 |
Enterprise Value | $97.73B | $47.12B |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $242.93, down 1.32% on the day, with a bullish technical signal and strong fundamentals including a P/E of 8.85 and net income margin of 21.58%. Recent corporate actions include a 2:1 reverse stock split and consistent dividend payments. The stock shows robust earnings beats in recent quarters, though Q3 2026 results are pending.
The outlook is positive with a consensus price target of $320.54, indicating significant upside. Risks include recent growth guidance disappointments and competitive pressures in industrial automation. Analyst sentiment is predominantly buy-rated, supporting a favorable investment case amid ongoing portfolio simplification.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
